» Articles » PMID: 38467248

Amplification of Mutant NRAS in Melanocytic Tumors With Features of Spitz Tumors

Overview
Journal Mod Pathol
Specialty Pathology
Date 2024 Mar 11
PMID 38467248
Authors
Affiliations
Soon will be listed here.
Abstract

NRAS activating mutations are prevalent in melanocytic neoplasia, occurring in a subset of common acquired melanocytic nevi and ∼30% of cutaneous melanomas. In this study, we described a cohort of 7 distinctive melanocytic tumors characterized by activating point mutations in codon 61 of NRAS with amplification of the mutant NRAS allele and shared clinicopathologic features. These tumors occurred predominantly in younger patients, with a median age of 20 years (range, 6-56 years). They presented as papules on the helix of the ear (4 cases) or extremities (3 cases). Microscopically, the tumors were cellular, relatively well-circumscribed, compound, or intradermal proliferations. The tumor cells often extended into the deep reticular dermis and involved the superficial subcutaneous fat in some cases. The melanocytes were epithelioid to spindled with moderate amounts of cytoplasm and conspicuous nucleoli. They were arranged in short plexiform fascicles, nests, and cords. Some cases had occasional pleomorphic and multinucleated melanocytes. Rare dermal mitotic figures were present in all cases. The dermis contained thick collagen bundles and minimal solar elastosis. Follow-up data were available for 5 patients, with a median period of 4.2 years (range, 1-9 years), during which no recurrences or metastases were reported. Our series highlights a clinicopathologically and molecularly distinctive subset of NRAS-mutated tumors with amplification of the mutant NRAS allele.

Citing Articles

Spitz tumours and mimickers.

De la Fouchardiere A, Mazzei M, Pastor M, Forster A, Prieto V Virchows Arch. 2024; 486(1):143-164.

PMID: 39500756 DOI: 10.1007/s00428-024-03958-7.


Feasibility and Impact of Embedding an Extended DNA and RNA Tissue-Based Sequencing Panel for the Routine Care of Patients with Advanced Melanoma in Spain.

Castrejon N, Martin R, Carrasco A, Castillo P, Garcia A, Albero-Gonzalez R Int J Mol Sci. 2024; 25(13).

PMID: 39000050 PMC: 11241382. DOI: 10.3390/ijms25136942.